New Zealand’s medicines regulator approved two named psychiatrists this week to prescribe pharmaceutical-grade MDMA to patients with severe PTSD. That makes New Zealand only the second country in the world where this is legal, after Australia did the same thing in 2023. Both countries got there without ever approving MDMA as an actual medicine. The path they used instead is worth understanding on its own terms, especially set against how differently the same drug, for the same condition, has fared in the United States.
What got approved, and what didn’t
Medsafe’s own statement is explicit about this: the decision does not approve MDMA as a medicine in New Zealand, and it doesn’t apply to any doctor beyond the two named psychiatrists, Dr. Gary Wynn in Wellington and Dr. Tom Paterson in Auckland. Any other psychiatrist who wants to prescribe MDMA for PTSD has to go through the same individual approval process themselves. This is a per-doctor authorization, not a drug approval, a fundamentally different regulatory object than what the FDA process in the US is built around. Wynn and Paterson spent more than a year working through that process, providing Medsafe with detailed information about their specific treatment protocol and the pharmaceutical-grade MDMA product they intended to use.
Why this pathway exists at all
Australia built this model first, in 2023, when its regulator down-scheduled MDMA and psilocybin specifically to allow individual, authorized psychiatrists to prescribe them outside a clinical trial, provided each psychiatrist follows an approved treatment protocol and gets separate approval from a human research ethics committee. New Zealand has now adopted essentially the same structure, and Wynn and Paterson are its second use, following a psychiatrist authorized to prescribe psilocybin for treatment-resistant depression there last year. Between the two countries, this is no longer a one-time exception. It’s a working, repeatable regulatory pathway that keeps getting used.
The contrast worth sitting with
Resilient Pharmaceuticals, the company holding the largest clinical dataset for MDMA-assisted therapy in PTSD, was rejected by the FDA in 2024, which cited insufficient evidence that the treatment was safe or effective. An August report from Psychedelic Alpha, citing unnamed sources familiar with the filing, said the company had resubmitted its application without conducting a new Phase 3 trial, betting that the existing data can be reinterpreted rather than replaced. Resilient itself has not publicly confirmed a resubmission, and its path back to the FDA remains unresolved. That’s the US route: one company, one dataset, one national approval standing between the drug and any patient in the country. New Zealand and Australia never had to resolve that fight at all. Their pathway sidesteps the question of whether MDMA-assisted therapy has cleared a national evidentiary bar entirely, asking instead whether a specific, individually vetted doctor can be trusted to use it responsibly with a specific patient.
What this pathway requires, and why it isn’t a shortcut around safety
Reading this as regulatory laxity would misread what’s happening. Authorized psychiatrists in both countries have to demonstrate real expertise, follow an approved clinical protocol, and get independent ethics committee sign-off, and the treatment itself keeps every safeguard associated with clinical MDMA-assisted therapy: adult-only, comprehensive clinical assessment beforehand, supervised dosing in a clinical setting, no take-home doses. The professional psychiatric college covering both countries has already published guidance recommending this treatment be reserved for patients who’ve exhausted other established options first. This is a narrower, more individually scrutinized form of access than a national approval would create, applied to fewer patients through fewer doctors, not a looser one.
What this means for how the US route gets read from here
Whatever Resilient’s next step at the FDA turns out to be, the question it faces is whether its existing data can satisfy the same regulatory bar that rejected it in 2024. That remains the real question for US patients specifically. But New Zealand and Australia’s approach is now a working answer to a related, separate question: whether MDMA-assisted therapy has to clear a national drug approval before any patient anywhere can access it responsibly. Two countries have already answered no, and built a functioning system around that answer. Whether that model could ever translate to the US regulatory structure is an open question, the FDA has no real equivalent to an individually authorized prescriber pathway for a Schedule I compound, but the fact that patient access and national drug approval have now been fully decoupled somewhere in the world is itself a real data point worth tracking as this story develops in both directions at once.
How small this is, and how unsettled the evidence remains
This program is small by design, two authorized psychiatrists in New Zealand, an unspecified but reportedly limited number in Australia, and Medsafe’s own statement stresses that treatment is expected to be suitable for only a limited number of patients. Evidence on MDMA for PTSD is still described by New Zealand’s own health ministry as emerging internationally, not settled, and this approval doesn’t resolve any of the underlying evidentiary questions the FDA raised in its 2024 rejection, it simply routes around needing to resolve them nationally before any patient can be treated.